Professional background

Dr Rowan Miller is a consultant medical oncologist specialising in gynae-oncology and early phase clinical trials at University College London and St Bartholomew's Hospitals.

Dr Miller completed her undergraduate training at the University of Oxford and clinical training at Guy's and St Thomas' Hospitals, London. She trained in medical oncology at University College London and was subsequently awarded a Cancer Research UK fellowship and attained a PhD from the Institute of Cancer Research. Following her PhD, Rowan completed a fellowship at Dana Farber Cancer Institute, Harvard University.

Rowan is involved in a number of clinical trials and basic science research projects across the two academic centres and is a member of the ESMO Personalized Medicine and Translational Research Committee.

Research interests

Clinical trials

  • Novel therapies for gynaecological cancer
  • Utilising genomics and biomarkers to guide therapy in patients
  • Clear cell ovarian cancer and other rare gynaecological cancers


Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, Cardin DB, Vieito M, Miller RE et al. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer 2022;10:e004235. doi:10.1136/jitc-2021-004235

Lee JM, Gao B, Miller R et al. A Phase 2 Study of Prexasertib (LY2606368) in Platinum Resistant or Refractory Recurrent Ovarian Cancer. Gynecologic Oncology. Sep 30;S0090-8258(22)01839-X.doi: 10.10

Miller RE, Elyashiv O, El-Shakankery KH and Ledermann JA. Ovarian cancer therapy: homologous recombination deficiency as a predictive biomarker of response to PARP inhibitors. Oncotargets 2022 15:1105-1117

Devlin MJ, Miller R, Laforets F et al. The tumour microenvironment of clear cell ovarian cancer. Cancer Immunol Res. 2022 Sep 12;CIR-22-0407.

Miller RE, El-Shakankery KH and Lee JY. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. J Gynecol Oncol. 2022 May;33(3):e44

Graham R, MacDonald ND, Lockley M, Miller R et al. Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study. European Journal of Obstetrics and Gynecology 271 (2022) 138–144

Miller RE. Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy. The Cancer Journal 2021 01;27(6):506-510.

Chandrasekaran D, Sobocan M, Blyuss O, Miller RE et al Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study. Cancers. 2021 Aug 27;13(17):4344. doi: 10.3390/cancers13174344

Miller RE, Lewis A and Powell ME. PARP Inhibitors and Immunotherapy in Ovarian and Endometrial Cancers. British Journal of Radiology. 021 Jun 9;20210002.doi: 10.1259/bjr.20210002
EL-Shakankery K, Kefas J and Miller RE.  COVID-19, the future vaccine and what it means for cancer patients on immunotherapy. Frontiers in Oncology. 01 February 2021 

Miller RE, Leary A, Scott C, Serra V et al. ESMO Recommendations on Predictive Biomarker Testing for Homologous Recombination Deficiency and PARP Inhibitor Benefit in Ovarian Cancer. Annals of Oncology. 2020 Dec;31(12):1606-1622

Hockings H, Wood G, McDermott J, Narayanan P, Hameeduddin A, Miller RE and Lockley M. Bevacizumab Enables Surgery in Previously Inoperable Patients with Advanced Low-Grade Serous Ovarian Cancer. European Journal of Surgery Case Reports. 2020 DOI: 10.47496/nl.EJSCR.2020.01.05
Crusz SM, El-Shakankery K and Miller RE. Targeting HPV in gynaecological cancers - current status, ongoing challenges and future directions. Clinical Medicine Insights: Women's Health. 2020 Jan-Dec;16: doi: 10.1177/1745506520961709.

Gourley C, Miller RE, Hollis RL & Ledermann JA. Role of PARP inhibitors beyond BRCA mutated ovarian tumours; definition of homologous recombination deficiency? Current Opinions in Oncology. 2020 Sep;32(5):442-450

Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim JS , Carreira S, Roda D, Miller R, et al Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Cancer Discovery.  2020 Jun 12; doi: 10.1158/2159-8290.CD-20-0163

Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R et al. Platinum sensitive relapsed high-grade serous ovarian cancer patients: real world UK clinical outcomes prior to PARP inhibitor introduction: International Journal of Gynecological Cancer. 2020 Jul;30(7):1026-1033.

Crusz SM and Miller RE. Targeted Therapies in Gynaecological Cancers. Histopathology. 2020 Jan;76(1):157-170

McGregor B, Miller RE, O'Donnell E, Albiges LK, Sweeney CJ and Markt S. Body Mass Index and outcomes in germ cell tumors. Clinical Genitourinary Cancer. 2019 Aug;17(4):283-290

Miller RE, Crusz SM and Ledermann JA. Olaparib maintenance for first-line treatment of ovarian cancer- Will SOLO1 reset the standard of care? Future Oncology 2019. 2019 Jun;15(16):1845-1853

Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T, Miller R et al. ESMO recommendations on microsatellite instability testing in cancer, and its relationship with PD-1/PD-L1 expression and tumor mutational load: a systematic review-based approach. Annals of Oncology. 2019 Aug 1;30(8):1232-1243

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, et al . Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Sci Rep. 2018 Jul 13;8(1):10614

Miller RE, Markt, SC, O’Donnell E, Bernard B, Albiges LK, Beard C, Sweeney CJ. Age ≥ 40 is associated with adverse outcome in metastatic germ cell cancer despite appropriate intended chemotherapy. Eur Urol Focus. 2017 Dec;3(6):621-628. doi: 10.1016/j.euf.2016.10.005

Markt, SC, O’Donnell E, Miller RE, Bernard B, Albiges LK, Beard C, Sweeney CJ. Smoking and disease outcomes in patients with malignant germ cell tumors. Clin Genitourin Cancer. 2017 Aug 3. pii: S1558-7673(17)30234-3

Miller RE and Ledermann JA. The European Society for Medical Oncology 2016 Congress: Highlights and summary of selected abstracts in gynecologic cancers. Gynecologic Oncology 2017 Jan;144(1):8-10.

Williamson CT, Miller R, Pemberton H, Jones SE, Campbell J, Kigozi A, Badham N, Rafiq R, Brough R, Gulati A, Ryan C, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A and Lord CJ. ATR inhibitors as a Synthetic Lethal Therapy for Tumors Deficient in ARID1A. Nature Communications 2016 Dec 13;7 

Miller RE and Ledermann JA. The status of PARP inhibitors in ovarian cancer. Part 2: Extending the scope beyond olaparib and BRCA 1/2 mutations. Clinical Advances in Hematology and Oncology 2016 Sep;14(9):704-11.

Miller RE and Ledermann JA. The status of PARP inhibitors in ovarian cancer. Part 1: Olaparib. Clinical Advances in Hematology and Oncology. Clinical Advances in Hematology & Oncology. 2016 Aug;14 (8):619-627

Markt SC, Lago-Hernandez, Miller RE, Mahal B, Bernard B, Albiges L, Frazier LA, Beard CJ, Wright AA, Sweeney CJ. Insurance Status and Disparities in Disease Presentation, Treatment and Outcomes in Men with Germ Cell Tumors. Cancer. 2016 Oct 15;122(20):3127-3135

Miller RE, Brough R, Bajrami I, Williamson C, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A. Synthetic Lethal Targeting of ARID1A Mutant Ovarian Clear Cell Tumours with Dasatinib. Mol Cancer Ther. 2016 Jul;15(7):1472-84

Kristeleit RS, Miller RE and Kohn EC. Gynecological Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency. Am Soc Clin Oncol Educ Book. 2016;35:e259-68

Miller RE and Sweeney CJ. Chemotherapy for Hormone Naïve Prostate Cancer. Prostate Cancer and Prostatic Diseases, 2016 Jun;19(2):139-44

Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton H, Chong I, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller RE, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ. Large Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell Rep. 2016 Mar 15;14(10):2490-501

Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP 1/2 Inhibitor Sensitivity. Cancer Research. 2014; 1;74(1):287-97

Miller RE and Banerjee S. The current state of pemetrexed in ovarian cancer. Expert Opinion Investigational Drugs. 2013; 22(9):1201-10

Neijenhuis S*, Bajrami I*, Miller R, Lord CJ, Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair (Amst). 2013; 1;12(6):394-402 * Co-first authors

Tan DS*, Miller RE* and Kaye SB. New perspectives on molecular targeted therapy in ovarian clear carcinoma. Br J Cancer. 2013; 30;108(8):1553-9. * Co-first authors

Miller RE, Dudderidge T, Seckl MJ, Huddart R, Rustin GJS and Christmas T. Pathological findings following primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours. BJUI 2013; 111 (4b): E146–E262

Miller RE, Illings RO and Whelan JS. Lung Carcinoma with hypertrophic osteoarthropathy in a teenager. Rare Tumours 2011; 3(1):25-26

Miller RE and Rustin GSJ. How to follow up patients with advanced epithelial ovarian cancer. Current Opinions in Oncology. 2010; 22(5):498-502

Miller RE and Larkin J. Combination systemic therapy for advanced renal cell carcinoma.  Oncologist 2009;14(12):1218-24

Hewish M, Miller R, Forster M and Smith I. Severe synergistic toxicity from docetaxel in a patient treated concurrently with protease inhibitors as part of HIV post-exposure prophylaxis: a case report. Journal of Medical Case Reports 2009; 3:8866